Advancing Cancer Research Through Next Generation Sequencing at Mays Cancer Center of UT Health San Antonio

圣安东尼奥 UT Health 梅斯癌症中心通过下一代测序推进癌症研究

• 批准号: 10684795
• 负责人: Zhao Lai
• 金额: $ 19.14万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10684795
• 关键词: Advanced Malignant Neoplasm; Area; Award; Biological Assay; Cancer Center; Cancer Center Support Grant; Caring; Catchment Area; Collaborations; Communities; Core Facility; Development; Education; Environment; Experimental Designs; Funding; Genomics; Grant; Health; High-Throughput Nucleotide Sequencing; Hispanic Populations; Infrastructure; Journals; Knowledge; Leadership; Letters; Malignant Childhood Neoplasm; Malignant Neoplasms; Methodology; Mission; NCI Center for Cancer Research; Peer Review; Procedures; Protocols documentation; Publications; Qualifying; Research; Research Personnel; Research Project Grants; Research Project Summaries; Resource Sharing; Scientist; Secure; Services; Specialist; Strategic Planning; Technology; Technology Assessment; Texas; Training; United States National Institutes of Health; Universities; anticancer research; cancer genome; cancer genomics; career development; improved; innovation; instrumentation; member; next generation sequencing; programs; recruit; skills; success; technology validation

Project Summary This Research Specialist (Core-based Scientist) R50 application seeks support for Dr. Zhao Lai, Director of the Next-Generation Sequencing Shared Resource (NGSSR) in the NCI-designated Mays Cancer Center (MCC; Ruben Mesa, PI) at the University of Texas Health San Antonio (UTHSA). Next-generation sequencing (NGS) is one of the most significant technological advances in cancer genome research. Dr. Lai’s mission through the NGSSR is to provide the cutting-edge genomics technology to the cancer community of MCC. The NGSSR began in 2011 as a core facility with a focus on genomics of pediatric cancer research. Dr. Lai was recruited as a highly qualified genomics scientist to lead the NGS facility. In 2014, the core was integrated into the Cancer Center Support Grant (CCSG) as a Shared Resource. As the NGSSR Director since its inception, Dr. Lai has guided the development of every aspect of this highly regarded Shared Resource (scored “Outstanding” in the successful CCSG renewal in 2020). She has developed and executed strategic plans for technology assessment and implementation, trained and supervised staff scientists, and created all standard operating procedures. Dr. Lai has secured two NIH S10 Shared Instrumentation grants to significantly enhance the genomic infrastructure at UTHSA, continuously established new protocols to expand NGS services to support diverse cancer research applications. She continues to assist investigators NGS projects ranging from experimental design through subsequent interpretation of experimental results, and establishes the extensive collaboration to develop integrative assays and customized protocols that contribute to the long-term success of the MCC’s research program. Under her scientific leadership, the NGSSR has quickly become an essential component in the MCC and fundamentally transformed the genomics research environment for its members. Since 2011, the NGSSR’s Cancer Center users have nearly quadrupled. Currently, the NGSSR supports >42 Cancer Center members and 18 NCI-funded research projects. Dr. Lai’s knowledge of NGS technology and her key intellectual contribution to NGS applications in many NCI-funded research projects have been widely recognized (see Letters of Support), with the NGSSR’s contributions to over 100 publications, many in high-impact peer-reviewed journals. This proposed R50 award will provide a more stable financial basis for the NGS facility, further concentrate Dr. Lai’s efforts on cancer-oriented methodology development, application innovation, and service improvement, and offer her more opportunities in career development in cancer genomics. This award will also allow the NGSSR to continue providing cutting-edge sequencing technology, services, education, and training to MCC cancer research community to provide better care for the unique Hispanic population in our catchment area.

项目概要 本次研究专家（核心科学家）R50申请寻求中科院主任赵来博士的支持 NCI 指定的梅斯癌症中心 (MCC) 的下一代测序共享资源 (NGSSR) Ruben Mesa，PI），德克萨斯大学健康圣安东尼奥分校 (UTHSA) 的下一代测序 (NGS)。 这是赖博士通过癌症基因组研究取得的最重要的技术进步之一。 NGSSR旨在为MCC的癌症界提供尖端的基因组学技术。 成立于 2011 年，作为核心机构，专注于儿科癌症基因组学研究。 一位高素质的基因组学科学家领导 NGS 设施。2014 年，该核心被整合到癌症中心。 赖博士自 NGSSR 成立以来一直担任中心支持补助金 (CCSG) 作为共享资源。 指导了这一备受推崇的共享资源各个方面的发展（在 她已于 2020 年成功更新 CCSG）。 和实施，培训和工作人员科学家，并创建了所有受监督的标准操作程序。 Lai 获得了两项 NIH S10 共享仪器拨款，以显着增强基因组基础设施 在 UTHSA，不断建立新的协议来扩展 NGS 服务，以支持多样化的癌症研究 她继续协助研究人员进行从实验设计到应用的 NGS 项目。 随后解释实验结果，并建立广泛的合作来开发 有助于 MCC 研究长期成功的综合分析和定制方案 在她的科学领导下，NGSSR 很快成为 MCC 的重要组成部分。 自 2011 年以来，NGSSR 彻底改变了其成员的基因组学研究环境。 目前，NGSSR 支持超过 42 名癌症中心成员和癌症中心用户几乎翻了两番。 18 个 NCI 资助的研究项目。赖博士对 NGS 技术的了解以及她对 NGS 技术的关键智力贡献。 NGS 在许多 NCI 资助的研究项目中的应用得到了广泛认可（参见支持信）， NGSSR 发表了 100 多篇出版物，其中许多发表在高影响力的同行评审期刊上。 拟议的 R50 奖励将为 NGS 设施提供更稳定的财务基础，进一步集中赖博士的 致力于癌症导向的方法论开发、应用创新和服务改进，并提供 她在癌症基因组学领域的职业发展有更多机会，该奖项也将使 NGSSR 能够 继续为 MCC 癌症提供尖端测序技术、服务、教育和培训 研究社区为我们流域内独特的西班牙裔人口提供更好的护理。

项目成果

Prevalence of genotoxic bacteria in men undergoing biopsy for prostate cancer.

接受前列腺癌活检的男性中遗传毒性细菌的患病率。

• 发表时间: 2023-05
• 作者: Lee, John;Wickes, Brian L;Fu, Jianmin;Brockman, Nohelli E;Garg, Harshit;Jobin, Christian;Johson;Leach, Robin;Lai, Zhao;Liss, Michael A
• 通讯作者: Liss, Michael A